Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients With Dedifferentiated Liposarcoma

The authors coordinated a first-in-kind Phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma with cellular studies interrogating the molecular basis of geroconversion.